64 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Novartis (Switzerland)CH6 papers
- Medical University of ViennaAT3 papers
- Statistics AustriaAT3 papers
- Novartis (China)CN2 papers
- University Hospital MagdeburgDE2 papers
- AstraZeneca (Sweden)SE1 paper
- Berry & Associates (United States)US1 paper
- Berry Consultants, LLC (United States)US1 paper
- Charité - Universitätsmedizin BerlinDE1 paper
- Constellium (United Kingdom)GB1 paper
- Franklin UniversityUS1 paper
- Institute of Neuroimmunology and Multiple SclerosisDE1 paper
Showing 2024Show all
2 papers · 1 filter
stat.ME2024★ 1 cited
Randomization-based Inference for MCP-Mod
Lukas Pin, Oleksandr Sverdlov, Frank Bretz +1
Dose selection is critical in pharmaceutical drug development, as it directly impacts therapeutic efficacy and patient safety of a drug. The Generalized Multiple Comparison Procedu…
stat.AP2024★ 3 cited
WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial Sponsors
Konstantinos Sechidis, Sophie Sun, Yao Chen +8
This paper proposes a Workflow for Assessing Treatment effeCt Heterogeneity (WATCH) in clinical drug development targeted at clinical trial sponsors. WATCH is designed to address t…